Emmes Group (The Emmes Company, LLC) was founded in 1977 in Rockville, Maryland, United States, with an initial focus on biostatistics and public sector research, establishing an early and enduring relationship with the US National Institutes of Health (NIH) as a scientific and operational partner. Over more than four decades, Emmes built an unmatched depth of engagement across NIH Institutes and Centers, contributing to critical research in infectious diseases, blood disorders, ophthalmology, and public health — most notably as a lead organisation on the landmark AREDS and AREDS2 trials that shaped international treatment guidelines for age-related macular degeneration, and as a long-standing supporter of haematopoietic stem cell transplantation (HSCT) research since 2001.

In June 2022, Emmes entered a private equity-backed growth phase through a strategic partnership with New Mountain Capital, which has since accelerated geographic expansion, site network growth, and a series of strategic acquisitions extending therapeutic expertise and geographic reach. Under this ownership, Emmes Group was restructured into two operating business units: Emmes CRO (the core clinical research organisation) and Veridix (the group’s technology and AI business unit), with both operating under The Emmes Company, LLC parent entity.

The company operates across more than 90 countries, with access to over 32,000 clinical trial sites and more than 60,000 platform users. It has conducted more than 2,000 clinical trials involving over one million participants. Its 98% client retention rate and a client relationship dating to 1981 indicate sustained sponsor confidence over a multi-decade operational history. The company has partnered with 15 of the top 25 biopharma companies in the past three years, alongside government agencies, non-profit organisations (including the Gates Foundation, PATH, and IAVI), and academic institutions.

Key Products and Services

Emmes CRO — Clinical Research Services

• Biostatistics — statistical analysis plan development, sample size calculations, randomisation design, adaptive study design, interim analysis, and final statistical analysis and reporting
• Clinical Data Management — eCRF design, database development, automated data review, medical coding (MedDRA and WHO Drug), CDISC compliance (SDTM, ADaM), query management, and database lock
• Clinical Research Services — site selection and management, monitoring (on-site and remote), study start-up, informed consent management, and patient and site engagement
• Clinical Trial Management — full project management encompassing timelines, budgets, risk management, vendor oversight, and milestone accountability
• Global Regulatory Affairs — regulatory strategy, IND and NDA/BLA submission support, agency meeting preparation, CTA submissions across global markets, and ongoing regulatory maintenance
• Pharmacovigilance and Medical Monitoring — adverse event processing, SAE management, expedited reporting, DSURs/PSURs, medical monitoring, and DSMB support

Emmes CRO — Therapeutic Specialties

Primary specialties: Vaccines and Infectious Disease (spanning nearly every epidemic and pandemic since 1977, including COVID-19, Ebola, HIV, malaria, dengue, and emerging pathogens); Ophthalmology (AMD, glaucoma, diabetic retinopathy, and rare eye diseases); Clinical Neuroscience (traumatic brain injury, stroke, epilepsy, autism, depression, schizophrenia, and substance use disorders); Rare Disease; Cell and Gene Therapy; and Government-sponsored research.

Additional specialties: Haematology (including HSCT), Oncology, Maternal and Child Health, and Medical Devices.

Veridix — Technology and AI Platform

• Advantage eClinical Cloud — described as the industry’s first fully unified eClinical platform, integrating EDC, decentralised clinical trial (DCT) tools, RTSM (randomisation and trial supply management), eCOA/ePRO, and the Health Navigator patient engagement application within a single cloud-based environment
• GlobalTrace — centralised oversight and control platform for biological specimen and biobank asset management, supporting sample integrity and chain-of-custody tracking across multi-site clinical programmes
• Clinical Pipelines — advanced and automated analytical capabilities for large and complex biological datasets, including omics data, supporting translational and precision medicine research applications
• AI Agents:
  • Biostats and Analysis Agent — AI-assisted statistical analysis and reporting within clinical research workflows
  • Data Management Agent — automated data management processes including query generation, coding, and review
  • Document Authoring Agent — AI-assisted authoring of clinical research documents including CSRs, protocols, and regulatory submissions
• VERA (AI Reporting Agent) — AI-powered analytics and reporting agent for real-time clinical trial performance intelligence

Emmes Group occupies a distinctive position in the mid-tier CRO landscape, combining a 45-year institutional heritage — rooted in scientific rigour, government partnership, and public health research — with a private equity-backed growth agenda that has accelerated commercial expansion, technology investment, and therapeutic breadth. Its foundational relationship with the NIH and its track record across nearly every major infectious disease outbreak since 1977 provide credibility in vaccines and infectious disease that very few CROs of comparable size can claim, and its ophthalmology heritage — built through landmark NIH-sponsored trials — gives it a similarly established position in that specialist indication. The Veridix business unit represents a deliberate strategic bet on AI-native clinical research delivery, with the company self-positioning as the industry’s first native digital and AI specialty CRO — a claim that reflects the integration of AI agents directly into biostatistics, data management, and document authoring workflows rather than the peripheral AI tooling adopted by many larger CROs. The 98% client retention rate is the most striking single metric in the company’s public profile, and its maintenance over decades indicates a consistency of scientific and operational delivery that resonates with sponsors running complex, long-duration programmes in difficult therapeutic areas.